News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
172,810 Results
Type
Article (6963)
Company Profile (111)
Press Release (165736)
Section
Business (54944)
Career Advice (355)
Deals (9958)
Drug Delivery (30)
Drug Development (32426)
Employer Resources (69)
FDA (2795)
Job Trends (4182)
News (98359)
Policy (6910)
Tag
2024 BioCapital Digital (3)
2024 BioForest Digital (1)
2024 BioForest Standard (1)
2024 BioMidwest Digital (4)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Biotech Bay Standard (6)
2024 Biotech Beach Digital (2)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (1)
2024 Genetown Standard (4)
2024 Lone Star Bio Digital (6)
2024 Pharm Country Digital (3)
2024 Pharm Country Standard (2)
2025 Lone Star Bio Digital (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (265)
Adcomms (2)
Allergies (25)
Alliances (12589)
ALS (28)
Alzheimer's disease (386)
Antibody-drug conjugate (ADC) (50)
Approvals (2811)
Artificial intelligence (66)
Autoimmune disease (6)
Automation (1)
Bankruptcy (63)
Best Places to Work (3257)
BIOSECURE Act (14)
Biosimilars (36)
Biotechnology (73)
Bladder cancer (15)
Brain cancer (14)
Breast cancer (51)
Cancer (570)
Cardiovascular disease (34)
Career advice (304)
Career pathing (20)
CAR-T (50)
Cell therapy (127)
Cervical cancer (4)
Clinical research (27290)
Collaboration (246)
Compensation (230)
Complete response letters (7)
COVID-19 (667)
CRISPR (7)
C-suite (85)
Cystic fibrosis (27)
Data (658)
Decentralized trials (1)
Denatured (12)
Depression (15)
Diabetes (60)
Diagnostics (677)
Digital health (2)
Diversity (6)
Diversity, equity & inclusion (19)
Drug discovery (25)
Drug pricing (22)
Drug shortages (3)
Duchenne muscular dystrophy (14)
Earnings (23409)
Editorial (24)
Employer branding (10)
Employer resources (60)
Events (34391)
Executive appointments (268)
FDA (3089)
Featured Employer (21)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (183)
Gene editing (17)
Generative AI (9)
Gene therapy (75)
GLP-1 (234)
Government (735)
Guidances (16)
Healthcare (2439)
Huntington's disease (9)
IgA nephropathy (7)
Immunology and inflammation (29)
Indications (10)
Infectious disease (695)
Inflammatory bowel disease (46)
Inflation Reduction Act (6)
Influenza (7)
Intellectual property (32)
Interviews (58)
IPO (5832)
IRA (14)
Job creations (1032)
Job search strategy (260)
Kidney cancer (5)
Labor market (22)
Layoffs (124)
Leadership (11)
Legal (934)
Liver cancer (23)
Lung cancer (94)
Lymphoma (37)
Machine learning (2)
Management (23)
Manufacturing (101)
MASH (34)
Medical device (485)
Medtech (486)
Mergers & acquisitions (4336)
Metabolic disorders (206)
Multiple sclerosis (25)
NASH (8)
Neurodegenerative disease (24)
Neuropsychiatric disorders (7)
Neuroscience (552)
NextGen: Class of 2025 (1035)
Non-profit (259)
Northern California (951)
Now hiring (27)
Obesity (106)
Opinion (78)
Ovarian cancer (26)
Pain (21)
Pancreatic cancer (18)
Parkinson's disease (45)
Partnered (1)
Patents (62)
Patient recruitment (36)
Peanut (14)
People (17392)
Pharmaceutical (38)
Pharmacy benefit managers (1)
Phase I (8253)
Phase II (12613)
Phase III (9161)
Pipeline (357)
Podcasts (43)
Policy (53)
Postmarket research (516)
Preclinical (3104)
Press Release (19)
Prostate cancer (19)
Psychedelics (12)
Radiopharmaceuticals (111)
Rare diseases (97)
Real estate (1224)
Recruiting (29)
Regulatory (5777)
Reports (22)
Research institute (293)
Resumes & cover letters (40)
RSV (10)
Schizophrenia (37)
Series A (34)
Series B (19)
Service/supplier (4)
Sickle cell disease (8)
Southern California (747)
Special edition (16)
Sponsored (5)
Startups (980)
State (1)
Stomach cancer (1)
Supply chain (14)
The Weekly (31)
United States (7253)
Vaccines (152)
Venture capitalists (15)
Webinars (7)
Weight loss (56)
Women's health (7)
Worklife (10)
Date
Today (57)
Last 7 days (216)
Last 30 days (1108)
Last 365 days (12342)
2025 (2299)
2024 (12814)
2023 (14610)
2022 (16504)
2021 (18117)
2020 (15465)
2019 (10205)
2018 (7306)
2017 (9066)
2016 (7456)
2015 (9494)
2014 (7240)
2013 (5233)
2012 (5086)
2011 (4992)
2010 (4942)
Location
Africa (169)
Alabama (18)
Arizona (19)
Arkansas (2)
Asia (13680)
Australia (1682)
California (1992)
Canada (475)
China (267)
Colorado (74)
Connecticut (90)
Delaware (67)
Europe (24872)
Florida (262)
Georgia (63)
Idaho (4)
Illinois (97)
India (6)
Indiana (72)
Iowa (3)
Japan (52)
Kansas (50)
Kentucky (7)
Maine (2)
Maryland (253)
Massachusetts (1602)
Michigan (36)
Minnesota (72)
Missouri (15)
Nebraska (7)
Nevada (4)
New Hampshire (5)
New Jersey (722)
New Mexico (8)
New York (680)
North Carolina (338)
Northern California (951)
Ohio (63)
Oklahoma (3)
Oregon (12)
Pennsylvania (363)
Puerto Rico (3)
Rhode Island (6)
South America (231)
Southern California (747)
Tennessee (8)
Texas (201)
Utah (46)
Virginia (37)
Washington D.C. (12)
Washington State (137)
Wisconsin (9)
172,810 Results for "gt biopharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
GT Biopharma Announces Exercise of Warrants
February 25, 2025
·
4 min read
Press Releases
GT Biopharma to Participate in the 10th Anniversary of the Innate Killer Summit
March 5, 2025
·
3 min read
Press Releases
GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies
January 27, 2025
·
3 min read
Press Releases
GT Biopharma Reports Third Quarter 2024 Financial Results
November 14, 2024
·
10 min read
Drug Development
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia
GT Biopharma, Inc. today announced FDA clearance of its IND application for GTB-3650, allowing the company to proceed with a Phase 1 clinical trial, which is anticipated to start in second half of 2024.
June 27, 2024
·
5 min read
Business
GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager, TriKE® platform, today announced first quarter 2024 financial results for the period ended March 31, 2024.
May 15, 2024
·
10 min read
Business
GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results
GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP) today announced fourth quarter and full-year 2023 results for the period ended December 31, 2023.
March 26, 2024
·
7 min read
Press Releases
GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
September 27, 2024
·
3 min read
Deals
GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
GT Biopharma, Inc. (NASDAQ: GTBP) (the “Company”), today announced that it has entered into a definitive securities purchase agreements for the purchase and sale of 740,000 shares of the Company’s common stock at a purchase price of $4.35 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules.
May 21, 2024
·
4 min read
Deals
GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split
GT Biopharma, Inc. announced today that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30.
February 1, 2024
·
4 min read
1 of 17,281
Next
